400-9696-311 转1
400-9696-311 转3
400-9696-311 转4
400-9696-311 转5
400客服电话
购买数据产品
400-9696-311 转1
定制咨询业务
400-9696-311 转2
数据与AI定制业务
400-9696-311 转3
商务合作及其他问题
400-9696-311 转4
投诉及建议
400-9696-311 转5
2017-10-02
FDA-2003-D-0378
指导原则
美国
现行有效
/
美国食品药品监督管理局(FDA)
GUIDANCE DOCUMENT
The Medical Device User Fee Amendments of 2017 (MDUFA IV), amended the Federal Food, Drug, and Cosmetic Act (the Act) to authorize FDA to collect user fees for the review of certain premarket submissions received on or after October 1, 2017, including premarket approval applications (PMAs). The additional funds obtained from user fees will enable FDA, with the cooperation of industry, to improve the device review process to meet certain performance goals and implement improvements for the medical device review process.
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2003-D-0378.
摩熵医药2026-06-17
摩熵医药2026-06-09
赛柏蓝2026-06-01
深蓝观2026-05-22
赛柏蓝2026-04-24
摩熵医械2026-01-28
摩熵医械2026-01-13
摩熵医械2025-12-19
赛柏蓝2025-12-12
摩熵医械2025-11-28
2026-07-15
2026-07-03
2026-07-03
2026-07-02
2026-06-30
2026-06-25
2026-06-24
2026-06-23
2026-06-15
2026-06-01
2026-06-01
2026-05-25
2026-05-20
2026-05-13
2026-05-13
2024-11-15
2024-11-14
2024-11-01
2024-10-31
2024-10-30
2024-10-24
2024-10-22
2024-10-21
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-17
2024-10-16
2024-10-15
2026-05-13
2026-05-13
2026-05-13
2026-05-13
2026-05-13
2026-05-08
2026-05-08
2026-05-08
2026-05-08
2026-05-07
2026-05-06
2026-05-05
2026-04-21
2026-04-20
2026-04-20